HEPATITIS/HIV PROJECT DESCRIPTION
Worldwide, more than 2 billion people have been infected with hepatitis B virus (HBV); at least 350 million are chronically infected. An estimated 170 to 200 million people have been infected with hepatitis C virus (HCV); as many as 130 million are chronically infected. Both viruses can lead to cirrhosis, liver cancer, and liver failure.
Globally, 6 to 9 million HIV-positive people are coinfected with viral hepatitis. End-stage liver disease from viral hepatitis coinfection has become a leading cause of death among HIV-positive people in the United States and Europe. HIV accelerates liver disease progression, and viral hepatitis is more difficult to treat in HIV-positive people.
Treatment Action Group’s Hepatitis/HIV Project collaborates with activists, community members, scientists, governments, and drug companies to make safer, more effective and less toxic treatment for viral hepatitis available. The Project forges coalitions with activists worldwide to demand universal access to hepatitis care and treatment.
The Hepatitis/HIV Project fights for research to address the unmet needs of people with viral hepatitis and HIV. It works with activists, community members, the U.S. Food and Drug Administration, and the European Medicines Agency to urge the pharmaceutical industry to study drugs and develop treatment strategies in real-world populations, including people coinfected with HIV and viral hepatitis; African Americans; people with advanced liver disease; current and former drug users; and people unresponsive to existing treatments.
The Hepatitis/HIV Project works to assure that:
- policy makers and researchers recognize and act on the priorities of people living with these viruses
- clinical and operational research on viral hepatitis is efficient, relevant, and well-designed
- new treatments for viral hepatitis are tested in people with the greatest need, as soon as it is safe to do so
- accurate and timely information about hepatitis prevention, care, and treatment is available to people living with HIV and viral hepatitis, treatment activists, health care providers, advocates, educators, people working in harm reduction, and drug treatment program staff
- all coinfected people have access to safe and effective treatment for HIV and viral hepatitis